x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243036
| Product Information | |
|---|---|
| CAS No. | 1314533-27-1 |
| Synonyms | MSDC-0602K |
| Formula | C19H16KNO5S |
| Molecular Weight | 409.50 |
| SMILES | O=C1SC(CC2=CC=C(C=C2)OCC(C3=CC(OC)=CC=C3)=O)C([N+]1)=O.[K-] |
| Target | Insulin Receptor, PPAR |
| Product Description | Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance. Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | White to off-white |
| Purity | 99.53% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
